Europe
There is new research out of Iceland that suggests the body’s immune response to COVID-19 lasts longer than other research has suggested.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
According to new data from the EAST-AFNET 4 trial that was released on Aug. 29, patients with atrial fibrillation appear to benefit from early rhythm control therapy.
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.
The U.S. expansion will recruit up to 30,000 adults over the age of 18 years from a broad range of racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions.
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
PRESS RELEASES